ClinicalTrials.gg
Active, not recruitingNCT04437511Updated Aug 26, 2026Results posted

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

A Phase 3 interventional study of Donanemab and Placebo in Alzheimer Disease, sponsored by Eli Lilly and Company. Active, not recruiting at 274 sites in 9 countries. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,736
Allocation
Randomized
Ages
60 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.

Enrollment
2nd of 15
1,736 · median 240
Started
2020
with 1 other
Phase 3
6 of 15
2 open now
Registered
4th of 15
by date
Lead sponsor
12 of 15
Eli Lilly and Company

Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 2nd largest by enrollment, is one of 2 that started in 2020, is one of 6 in phase 3, and was the 4th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About donanemab

donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing donanemab in Alzheimer Disease, or all of them as a file.
02

Study summary

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.

Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.

Trial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up.

Read the detailed description

TRAILBLAZER-ALZ 2 is a Phase 3, double-blind, placebo-controlled study to evaluate the safety and efficacy of N3pG antibody (donanemab) in participants with early symptomatic AD (prodromal AD and mild dementia due to AD) with the presence of brain amyloid and tau pathology.

Following the double-blind 76-week main study period, a double-blind 78-week long-term extension period is added to further evaluate donanemab efficacy and safety over time. Participants from the addendum safety cohort are not eligible for the extension period.

Participants previously dosed with donanemab in the main study will be monitored to track re-accumulation of amyloid plaque for 3 years.

03

Conditions studied

  • Alzheimer Disease

Keywords

  • Alzheimer's
  • Dementia
  • Cognitive Impairment
  • Amyloid Plaque
04

Who can participate

Ages eligible
60 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gradual and progressive change in memory function reported by participants or informants for ≥ 6 months
  • score of 20 to 28 (inclusive) at baseline
  • Meet 18F flortaucipir PET scan (central read) criteria - does not apply to safety cohort
  • Meet 18F florbetapir PET scan (central read) criteria
  • Have a study partner who will provide written to participate

Exclusion criteria

Exclusion Criteria:

  • to MRI or PET scans
  • Current treatment with immunoglobulin G (IgG) therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,736 participants (actual)

Study arms

  • Experimental
    Donanemab

    Participants received 700 milligram (mg) Donanemab every 4 weeks (Q4W) x 3 doses, then 1400 mg Q4W given intravenously (IV) for up to 72 weeks

    Drug: Donanemab

  • Placebo comparator
    Placebo

    Participants received placebo given IV.

    Drug: Placebo

Interventions

  • Given IV

    Also known as: LY3002813

  • DrugPlacebo

    Given IV

06

What researchers measure

Primary outcomes

  1. Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)

    Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the ADAS-Cog13 and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. Least Squares (LS) Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline acetylcholinesterase inhibitor (AchI)/Memantine use.

    Time frame: Baseline, Week 76

  2. Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)

    Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

Secondary outcomes

  1. Change From Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population)

    MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  2. Change From Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population)

    MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  3. Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Overall Population)

    The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  4. Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population)

    The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-cog consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  5. Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population)

    CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, baseline tau category, pooled investigator, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  6. Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population)

    CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, pooled investigator, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  7. Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population)

    The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  8. Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population)

    The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

    Time frame: Baseline, Week 76

  9. Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan

    Amyloid PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical brain regions relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, baseline tau category, and age at baseline.

    Time frame: Baseline, Week 76

  10. Change From Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan

    Flortaucipir PET imaging was used as a quantitative tau biomarker. Tau PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in aggregated tau neurofibrillary tangles (NFTs). Quantitative tau burden was formalized using Standardized Uptake Value Ratio (SUVR) in frontal lobe relative to the cerebellum gray as a reference region. Larger SUVR reflects larger tau burden in the frontal lobe relative to cerebellum gray. LS Mean value was adjusted for baseline score, screening tau category, age and treatment (Type III sum of squares).

    Time frame: Baseline, Week 76

  11. Change From Baseline in Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)

    MRI scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in brain volume. Volumetric MRI parameters were measured in bilateral hippocampus, bilateral whole brain, and bilateral ventricles. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline tau category, and age at baseline.

    Time frame: Baseline, Week 76

  12. Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab

    The average serum concentration at steady state, calculated as Cav = AUCtau/tau, where tau is the dosing interval (4 weeks). AUCtau/tau was assessed at week 12, 16, 24, 36, 52, 64 and Cav for the dosing interval from week 16 to week 20 is reported.

    Time frame: Week 16 to week 20

  13. Number or Participants With Anti-Donanemab Antibodies

    Number of participants with treatment-emergent positive Anti-Donanemab antibodies was summarized by treatment group.

    Time frame: Baseline through Week 76

07

Results

Posted May 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneDonanemabPlacebo
Started860876
Received at least one dose of drug (safety population)853874
Completed622698
Not completed238178
Withdrew: Adverse event5021
Withdrew: Death1510
Withdrew: Lost to follow-up1111
Withdrew: Physician decision1910
Withdrew: Progressive disease47
Withdrew: Withdrawal by subject11194
Withdrew: Withdrawal due to caregiver circumstances2120
Withdrew: Continuing study75

Outcome measures

PrimaryChange From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)

Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the ADAS-Cog13 and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. Least Squares (LS) Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline acetylcholinesterase inhibitor (AchI)/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)-10.19 ± 0.53-13.11 ± 0.50
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): 2.92 · 95% CI 1.508 to 4.331
PrimaryChange From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)

Integrated Alzheimer's Disease Rating Scale is used to assess whether donanemab slows down the clinical decline associated with AD compared with placebo. iADRS is an integrated assessment of cognition and daily function comprised of items from the Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog13) and the Alzheimer's disease cooperative study-instrumental activities of daily living scale (ADCS-iADL). The scale ranges from 0 to 144, where lower scores indicate worse performance and higher score indicates better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)-6.02 ± 0.50-9.27 ± 0.49
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): 3.25 · 95% CI 1.883 to 4.618
SecondaryChange From Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population)

MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Mini Mental State Examination (MMSE) Score (Overall Population)-2.47 ± 0.14-2.94 ± 0.13
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = 0.012 · Ls mean change difference (final values): 0.47 · 95% CI 0.104 to 0.841
SecondaryChange From Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population)

MMSE is an instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30; lower score indicates greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Mini Mental State Examination (MMSE) Score (Intermediate (Low-medium) Tau Population)-1.61 ± 0.14-2.09 ± 0.14
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = 0.016 · Ls mean change difference (final values): 0.48 · 95% CI 0.089 to 0.868
SecondaryChange From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Overall Population)

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Overall Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Overall Population)5.46 ± 0.286.79 ± 0.27
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = 0.0006 · Ls mean change difference (final values): -1.33 · 95% CI -2.086 to -0.565
SecondaryChange From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population)

The ADAS is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-cog consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Intermediate (Low-medium) Tau Population)3.17 ± 0.274.69 ± 0.26
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): -1.52 · 95% CI -2.250 to -0.794
SecondaryChange From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population)

CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, baseline tau category, pooled investigator, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Overall Population)1.72 ± 0.0962.42 ± 0.092
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): -0.70 · 95% CI -0.95 to -0.45
SecondaryChange From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population)

CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, age at baseline, pooled investigator, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) (Intermediate (Low-medium) Tau Population)1.20 ± 0.1051.88 ± 0.102
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): -0.67 · 95% CI -0.95 to -0.40
SecondaryChange From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population)

The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, baseline tau level, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Overall Population)-4.42 ± 0.32-6.13 ± 0.30
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = 0.0001 · Ls mean change difference (final values): 1.70 · 95% CI 0.840 to 2.566
SecondaryChange From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population)

The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities (instrumental activity items 6a, 7-23) of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean value was adjusted for basis expansion terms (two terms), basis expansion term-by-treatment interaction, and covariates for age at baseline, pooled investigator, and baseline AchI/Memantine use.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · score on a scale
Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population)
score on a scaleDonanemabPlacebo
Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL) Score (Intermediate (Low-medium) Tau Population)-2.76 ± 0.34-4.59 ± 0.32
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): 1.83 · 95% CI 0.913 to 2.748
SecondaryChange From Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan

Amyloid PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical brain regions relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline score-by-visit interaction, baseline tau category, and age at baseline.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · centiloids
Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan
centiloidsDonanemabPlacebo
Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Amyloid Positron Emission Tomography (PET) Scan-87.03 ± 0.950-0.67 ± 0.909
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.0001 · Ls mean change difference (final values): -86.37 · 95% CI -88.87 to -83.87
SecondaryChange From Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan

Flortaucipir PET imaging was used as a quantitative tau biomarker. Tau PET scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in aggregated tau neurofibrillary tangles (NFTs). Quantitative tau burden was formalized using Standardized Uptake Value Ratio (SUVR) in frontal lobe relative to the cerebellum gray as a reference region. Larger SUVR reflects larger tau burden in the frontal lobe relative to cerebellum gray. LS Mean value was adjusted for baseline score, screening tau category, age and treatment (Type III sum of squares).

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · standardized uptake value ratio (SUVR)
Change From Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan
standardized uptake value ratio (SUVR)DonanemabPlacebo
Change From Baseline in Brain Tau Deposition as Measured by Flortaucipir F18 PET Scan0.0401 ± 0.003980.0442 ± 0.00374
Statistical analysis
  • Donanemab vs Placebo · ANCOVA · p = 0.4522 · Ls mean change difference (final values): -0.0041 · 95% CI -0.0148 to 0.0066
SecondaryChange From Baseline in Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)

MRI scans at baseline and at 76 weeks after the first treatment were used to quantitatively estimate change in brain volume. Volumetric MRI parameters were measured in bilateral hippocampus, bilateral whole brain, and bilateral ventricles. LS Mean value was adjusted for treatment, visit, treatment-by-visit interaction, and covariates for baseline score, baseline tau category, and age at baseline.

Time frame:
Baseline, Week 76
Reported as:
Least squares mean · cubic centimeter (cm^3)
Change From Baseline in Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)
cubic centimeter (cm^3)DonanemabPlacebo
Bilateral Hippocampus-0.20 ± 0.005-0.22 ± 0.005
Bilateral Whole Brain-27.46 ± 0.409-20.79 ± 0.392
Bilateral Ventricles10.07 ± 0.1857.05 ± 0.178
Statistical analysis
  • Donanemab vs Placebo · Mixed Models Analysis · p = 0.002 · Ls mean change difference (final values): 0.02 · 95% CI 0.01 to 0.04
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): -6.66 · 95% CI -7.76 to -5.56
  • Donanemab vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean change difference (final values): 3.02 · 95% CI 2.52 to 3.52
SecondaryPharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab

The average serum concentration at steady state, calculated as Cav = AUCtau/tau, where tau is the dosing interval (4 weeks). AUCtau/tau was assessed at week 12, 16, 24, 36, 52, 64 and Cav for the dosing interval from week 16 to week 20 is reported.

Time frame:
Week 16 to week 20
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab
micrograms per milliliter (μg/mL)Donanemab
Pharmacokinetics (PK): Average Serum Concentration at Steady State of Donanemab63 ± 32
SecondaryNumber or Participants With Anti-Donanemab Antibodies

Number of participants with treatment-emergent positive Anti-Donanemab antibodies was summarized by treatment group.

Time frame:
Baseline through Week 76
Reported as:
Count of participants · Participants
Number or Participants With Anti-Donanemab Antibodies
ParticipantsDonanemabPlacebo
Number or Participants With Anti-Donanemab Antibodies69348

Adverse events

Collected over Baseline Up To 76 Weeks plus 57 Days (Follow-up period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donanemab16/853 (1.9%)148/853 (17.4%)567/853 (66.5%)
Placebo10/874 (1.1%)138/874 (15.8%)425/874 (48.6%)
Most frequent serious events
Showing 10 of 204
Most frequent serious events
EventDonanemabPlacebo
Amyloid related imaging abnormality-oedema/effusionNervous system disorders13/8530/874
SyncopeNervous system disorders9/85313/874
Covid-19Infections and infestations9/8534/874
Acute myocardial infarctionCardiac disorders5/8530/874
PneumoniaInfections and infestations5/8535/874
FallInjury, poisoning and procedural complications5/8531/874
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3651/373
Benign prostatic hyperplasiaReproductive system and breast disorders2/3650/373
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsNervous system disorders4/8530/874
AgitationPsychiatric disorders4/8531/874
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDonanemabPlacebo
Amyloid related imaging abnormality-oedema/effusionNervous system disorders200/85317/874
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsNervous system disorders166/85365/874
Covid-19Infections and infestations130/853150/874
HeadacheNervous system disorders119/85386/874
FallInjury, poisoning and procedural complications111/853109/874
Infusion related reactionInjury, poisoning and procedural complications73/8534/874
Superficial siderosis of central nervous systemNervous system disorders58/85310/874
Urinary tract infectionInfections and infestations42/85356/874
DizzinessNervous system disorders52/85348/874
ArthralgiaMusculoskeletal and connective tissue disorders49/85341/874

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)DonanemabPlaceboTotal
Mean72.98 ± 6.1673.04 ± 6.2073.01 ± 6.18
Sex/Gender, Customized
Sex/Gender, Customized(participants)DonanemabPlaceboTotal
Female488501989
Male365373738
Sex: Female, Male
Sex: Female, Male(Participants)DonanemabPlaceboTotal
Female493503996
Male367373740
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DonanemabPlaceboTotal
Hispanic or Latino353671
Not Hispanic or Latino5835941177
Unknown or Not Reported242246488
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DonanemabPlaceboTotal
American Indian or Alaska Native202
Asian5747104
Native Hawaiian or Other Pacific Islander000
Black or African American192140
White7818071588
More than one race011
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)DonanemabPlaceboTotal
Australia13417
Canada6473137
Czechia121022
Japan454388
Netherlands13922
Poland7782159
United Kingdom162339
United States6206321252
Integrated Alzheimer's Disease Rating Scale (iADRS)
Integrated Alzheimer's Disease Rating Scale (iADRS)(Score on a scale)DonanemabPlaceboTotal
Mean104.10 ± 14.30103.56 ± 14.02103.83 ± 14.16
Screening Tau Category
Screening Tau Category(Participants)DonanemabPlaceboTotal
Intermediate (Low-medium)5885941182
High271281552
08

Study locations

274 sites

Showing the first 100 of 274 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Brookfield N, Hauck PM, Doty EG, Zimmer JA, Yang F, Chen YF, Ardayfio P, Khanna R, Ye W, Tockhorn-Heidenreich A, Patel N. Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE epsilon4. Neurodegener Dis Manag. 2026 Aug 26:1-11. doi: 10.1080/17582024.2026.2723524. Online ahead of print. PubMed 42644303 ↗
  • Boustani M, Klein EG, Zimmer JA, Wang H, Engle SE, Phipps A, Japha M, Schilling T, Hartry A; Alzheimer's Disease Neuroimaging Initiative. Further data to address the Alzheimer's coverage with evidence development questions. Alzheimers Dement. 2026 Aug;22(8):e71724. doi: 10.1002/alz.71724. PubMed 42552749 ↗
  • Raket LL, Lu M, Evans CD, Zimmer JA, Sparks J, Collins EC, Shcherbinin S, Wang H, Nery ESM, Epelbaum S, Dell'Agnello G, Brooks DA, Sims JR, Mintun MA. Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial. Alzheimers Dement. 2026 Jun;22(6):e71577. doi: 10.1002/alz.71577. PubMed 42273802 ↗
  • Atri A, Apostolova LG, Iwata A, Wessels AM, Atkins A, Lu M, Ye W, Ryan S, Doty EG. Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial. Neurol Clin Pract. 2026 Jun;16(3):e200621. doi: 10.1212/CPJ.0000000000200621. Epub 2026 May 13. PubMed 42128444 ↗
  • Ardayfio P, Mullins GR, Khanna R, Zimmer JA, Wang H, Nery ESM, Evans CD, Piela P, Battioui C, Lauzon S, Anglin G, Ng HW, Jayaraman AR, Agada N, Natalie CR, Brooks DA, Sims JR. Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's disease. Alzheimers Dement (N Y). 2026 Mar 8;12(1):e70229. doi: 10.1002/trc2.70229. eCollection 2026 Jan-Mar. PubMed 41804324 ↗
  • Zimmer JA, Sims JR, Evans CD, Nery ESM, Wang H, Wessels AM, Tronchin G, Sato S, Raket LL, Andersen SW, Sapin C, Paget MA, Gueorguieva I, Ardayfio P, Khanna R, Brooks DA, Matthews BR, Mintun MA; Alzheimer's Disease Neuroimaging Initiative. Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. J Prev Alzheimers Dis. 2026 Feb;13(2):100446. doi: 10.1016/j.tjpad.2025.100446. Epub 2025 Dec 1. PubMed 41330788 ↗
  • Lu M, Kim MJ, Collins EC, Shcherbinin S, Ellinwood AK, Yokoi Y, Brooks DA, Hansson O, Knopman DS, Sims JR, Mintun MA. Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA Neurol. 2025 Dec 1;82(12):1251-1256. doi: 10.1001/jamaneurol.2025.3869. PubMed 41082199 ↗
  • Gueorguieva I, Chow K, Chua L, Shcherbinin S, Zimmer JA, Evans CD, Wang H, Nery ESM, Brooks DA, Sims JR. Donanemab exposure-response in early symptomatic Alzheimer's disease. Alzheimers Dement. 2025 Jul;21(7):e70491. doi: 10.1002/alz.70491. PubMed 40667684 ↗
  • Chandler JM, Lansdall CJ, Ye W, McDougall F, Belger M, Toth B, Mi X, Sink KM, Atkins AS. The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity. J Prev Alzheimers Dis. 2025 Sep;12(8):100261. doi: 10.1016/j.tjpad.2025.100261. Epub 2025 Jul 1. PubMed 40603145 ↗
  • Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, Battioui C, Engle SE, Biffi A, Svaldi D, Salloway S, Greenberg SM, Sperling RA, Mintun M, Brooks DA, Sims JR. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA Neurol. 2025 May 1;82(5):461-469. doi: 10.1001/jamaneurol.2025.0065. PubMed 40063015 ↗
  • Boustani M, Doty EG, Garrison LP Jr, Smolen LJ, Klein TM, Murphy DR, Spargo AW, Belger M, Johnston JA. Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States. Neurol Ther. 2024 Dec;13(6):1641-1659. doi: 10.1007/s40120-024-00649-y. Epub 2024 Sep 18. PubMed 39292433 ↗
  • Sato S, Hatakeyama N, Fujikoshi S, Katayama S, Katagiri H, Sims JR. Donanemab in Japanese Patients with Early Alzheimer's Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial. Neurol Ther. 2024 Jun;13(3):677-695. doi: 10.1007/s40120-024-00604-x. Epub 2024 Apr 6. PubMed 38581616 ↗
  • Klein EG, Schroeder K, Wessels AM, Phipps A, Japha M, Schilling T, Zimmer JA. How donanemab data address the coverage with evidence development questions. Alzheimers Dement. 2024 Apr;20(4):3127-3140. doi: 10.1002/alz.13700. Epub 2024 Feb 7. PubMed 38323738 ↗
  • Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. PubMed 37459141 ↗
  • Brodtmann A, Darby D, Oboudiyat C, Mahoney CJ, Le Heron C, Panegyres PK, Brew B. Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems. Med J Aust. 2023 Apr 3;218(6):247-249. doi: 10.5694/mja2.51880. Epub 2023 Mar 19. No abstract available. PubMed 36934371 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Apr 2023, 33 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 33 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2020
First posted
Jun 18, 2020
StartActual
Jun 19, 2020
Primary completionActual
Apr 14, 2023
CompletionEst.
Nov 2028
Results first posted
May 20, 2024
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04437511
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Jun 19, 2020
Primary completion
Apr 14, 2023
Completion
Nov 2028 (estimated)
Results posted
May 20, 2024
Last update
Aug 26, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion